Agenus logo

Agenus Share Price Today

(NASDAQ: AGEN)

Agenus share price is $2.41 & ₹209.83 as on 6 Mar 2025, 2.30 'hrs' IST

$2.41

-0.17

(-6.59%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Agenus share price in Dollar and Rupees. Guide to invest in Agenus stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Agenus, along with analyst recommendations, forecasts, and comprehensive financials.

Agenus share price movements

  • Today's Low: $2.37
    Today's High: $2.57

    Day's Volatility :7.6%

  • 52 Weeks Low: $2.37
    52 Weeks High: $19.69

    52 Weeks Volatility :87.96%

Agenus (AGEN) Returns

PeriodAgenus IncSector (Health Care)Index (Russel 2000)
3 Months
-23.25%
3.7%
0.0%
6 Months
-51.8%
-2.8%
0.0%
1 Year
-82.79%
2.5%
0.0%
3 Years
-95.87%
12.9%
-11.6%

Agenus (AGEN) Key Statistics

in dollars & INR

Previous Close
$2.58
Open
$2.59
Today's High
$2.565
Today's Low
$2.37
Market Capitalization
$60.9M
Today's Volume
$502.6K
52 Week High
$19.688
52 Week Low
$2.37
Revenue TTM
$160.4M
EBITDA
$-85.5M
Earnings Per Share (EPS)
$-11.26
Profit Margin
-141.9%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-1278.83%

How to invest in Agenus Stock (AGEN) from India?

It is very easy for Indian residents to invest directly in Agenus from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Agenus stock in both Indian Rupees (INR) and US Dollars (USD). Search for Agenus or AGEN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Agenus or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Agenus shares which would translate to 0.361 fractional shares of Agenus as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Agenus, in just a few clicks!

Returns in Agenus (AGEN) for Indian investors in Rupees

The Agenus stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Agenus investment value today

Current value as on today

₹22,279

Returns

₹77,721

(-77.72%)

Returns from Agenus Stock

₹82,786 (-82.79%)

Dollar Returns

₹5,065 (+5.06%)

Indian investors sentiment towards Agenus (AGEN)

-41%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Agenus Stock from India on INDmoney has decreased by -41% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Agenus

  • Vanguard Group Inc

    10.20%

  • BlackRock Inc

    6.99%

  • B. Riley Financial Inc

    3.21%

  • State Street Corp

    2.06%

  • Geode Capital Management, LLC

    2.01%

  • Morgan Stanley - Brokerage Accounts

    1.68%

Analyst Recommendation on Agenus

Buy

    90%Buy

    9%Hold

    0%Sell

Based on 11 Wall street analysts offering stock ratings for Agenus(by analysts ranked 0 to 5 stars)

Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Agenus Stock (AGEN)

What analysts predicted

Upside of 231.95%

Target:

$8.00

Current:

$2.41

Insights on Agenus Stock (Ticker Symbol: AGEN)

  • Price Movement

    In the last 7 days, AGEN stock has moved down by -15.7%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 23.50M → 25.11M (in $), with an average increase of 6.4% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -53.08M → -66.38M (in $), with an average decrease of 25.1% per quarter
  • AGEN vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 149.3%
  • AGEN vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 51.6% return, outperforming this stock by 147.5%
  • Price to Sales

    ForAGEN every $1 of sales, investors are willing to pay $0.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

AGEN Agenus Financials in INR & Dollars

FY18Y/Y Change
Revenue
$36.8M
↓ 14.21%
Net Income
$-159.7M
↑ 32.31%
Net Profit Margin
-434.14%
↓ 152.66%
FY19Y/Y Change
Revenue
$150.0M
↑ 307.92%
Net Income
$-149.1M
↓ 6.61%
Net Profit Margin
-99.39%
↑ 334.75%
FY20Y/Y Change
Revenue
$88.2M
↓ 41.24%
Net Income
$-240.1M
↑ 61.02%
Net Profit Margin
-272.35%
↓ 172.96%
FY21Y/Y Change
Revenue
$295.7M
↑ 235.34%
Net Income
$-94.7M
↓ 60.57%
Net Profit Margin
-32.03%
↑ 240.32%
FY22Y/Y Change
Revenue
$98.0M
↓ 66.85%
Net Income
$-271.5M
↑ 186.72%
Net Profit Margin
-276.99%
↓ 244.96%
FY23Y/Y Change
Revenue
$156.3M
↑ 59.47%
Net Income
$-245.8M
↓ 9.49%
Net Profit Margin
-157.22%
↑ 119.77%
Q2 FY23Q/Q Change
Revenue
$25.3M
↑ 10.45%
Net Income
$-73.4M
↑ 8.23%
Net Profit Margin
-290.28%
↑ 5.97%
Q3 FY23Q/Q Change
Revenue
$24.3M
↓ 3.88%
Net Income
$-62.2M
↓ 15.29%
Net Profit Margin
-255.82%
↑ 34.46%
Q4 FY23Q/Q Change
Revenue
$83.8M
↑ 244.66%
Net Income
$-46.3M
↓ 25.58%
Net Profit Margin
-55.24%
↑ 200.58%
Q1 FY24Q/Q Change
Revenue
$28.0M
↓ 66.58%
Net Income
$-61.9M
↑ 33.69%
Net Profit Margin
-220.98%
↓ 165.74%
Q2 FY24Q/Q Change
Revenue
$23.5M
↓ 16.05%
Net Income
$-53.1M
↓ 14.23%
Net Profit Margin
-225.79%
↓ 4.81%
Q3 FY24Q/Q Change
Revenue
$25.1M
↑ 6.82%
Net Income
$-66.4M
↑ 25.07%
Net Profit Margin
-264.36%
↓ 38.57%
FY18Y/Y Change
Profit
$-87.8M
↑ 19.89%
FY19Y/Y Change
Profit
$-18.3M
↓ 79.17%
FY20Y/Y Change
Profit
$-56.8M
↑ 210.51%
FY21Y/Y Change
Profit
$113.6M
↓ 299.99%
FY22Y/Y Change
Profit
$-99.2M
↓ 187.36%
FY23Y/Y Change
Profit
$-81.4M
↓ 18.01%
Q2 FY23Q/Q Change
Profit
$-34.2M
↓ 6.21%
Q3 FY23Q/Q Change
Profit
$-27.4M
↓ 19.89%
Q4 FY23Q/Q Change
Profit
$78.3M
↓ 385.58%
Q1 FY24Q/Q Change
Profit
$24.5M
↓ 68.7%
Q2 FY24Q/Q Change
Profit
$23.4M
↓ 4.61%
Q3 FY24Q/Q Change
Profit
$-16.1M
↓ 168.79%
FY18Y/Y Change
Operating Cash Flow
$-131.1M
↑ 39.13%
Investing Cash Flow
$-3.6M
↓ 273.98%
Financing Cash Flow
$128.3M
↑ 59.28%
FY19Y/Y Change
Operating Cash Flow
$-18.7M
↓ 85.75%
Investing Cash Flow
$-4.7M
↑ 29.69%
Financing Cash Flow
$31.3M
↓ 75.58%
FY20Y/Y Change
Operating Cash Flow
$-139.1M
↑ 644.55%
Investing Cash Flow
$-4.4M
↓ 4.64%
Financing Cash Flow
$183.9M
↑ 486.96%
FY21Y/Y Change
Operating Cash Flow
$10.1M
↓ 107.29%
Investing Cash Flow
$-43.2M
↑ 871.63%
Financing Cash Flow
$225.3M
↑ 22.52%
FY22Y/Y Change
Operating Cash Flow
$-175.4M
↓ 1828.66%
Investing Cash Flow
$-33.6M
↓ 22.11%
Financing Cash Flow
$95.8M
↓ 57.46%
Q2 FY23Q/Q Change
Operating Cash Flow
$-44.5M
↓ 23.99%
Investing Cash Flow
$517.0K
↓ 104.5%
Financing Cash Flow
$38.3M
↓ 31.98%

Agenus Technicals Summary

Sell

Neutral

Buy

Agenus is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Agenus (AGEN) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Agenus Inc logo
-31.14%
-51.8%
-82.79%
-95.87%
-94.87%
Regeneron Pharmaceuticals, Inc. logo
-1.42%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
17.63%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
1.94%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
-8.03%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Agenus Inc logo
0.46
NA
0.0
-12.02
-12.79
-0.22
NA
-13.48
Regeneron Pharmaceuticals, Inc. logo
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Agenus Inc logo
Buy
$60.9M
-94.87%
0.46
-141.9%
Regeneron Pharmaceuticals, Inc. logo
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.4B
126.66%
NA
-12.37%

About Agenus

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Organization
Agenus
Employees
389
CEO
Dr. Garo H. Armen Ph.D.
Industry
Health Technology

Management People of Agenus

NameTitle
Dr. Garo H. Armen Ph.D.
Founder, Executive Chairman & CEO
Ms. Christine M. Klaskin
VP of Finance, Principal Financial Officer & Principal Accounting Officer
Dr. Steven J. O'Day M.D., Ph.D.
Chief Medical Officer
Craig Winter
Chief Information Officer
Mr. Zack Armen
Head of Investor Relations & Corporate Development
Ms. Stefanie Perna-Nacar
Chief Communications & Government Relations Officer
Ms. Tracy Mazza Clemente
Chief People Officer
Mr. Alfred Dadson
Chief Manufacturing Officer
Mr. Eric Humes
Chief Quality Officer
Dr. Todd Jude Yancey M.D.
Member of Advisory Board & Chief Strategic Advisor

Important FAQs about investing in AGEN Stock from India :

What is Agenus share price today?

Agenus share price today stands at $2.41, Open: $2.59 ; Previous Close: $2.58 ; High: $2.57 ; Low: $2.37 ; 52 Week High: $19.69 ; 52 Week Low: $2.37.

The stock opens at $2.59, after a previous close of $2.58. The stock reached a daily high of $2.57 and a low of $2.37, with a 52-week high of $19.69 and a 52-week low of $2.37.

Can Indians buy Agenus shares?

Yes, Indians can invest in the Agenus (AGEN) from India.

With INDmoney, you can buy Agenus at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Agenus at zero transaction cost.

How can I buy Agenus shares from India?

It is very easy to buy Agenus from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Agenus (AGEN) be purchased?

Yes, you can buy fractional shares of Agenus with INDmoney app.

What are the documents required to start investing in Agenus stocks?

To start investing in Agenus, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Agenus Stock (AGEN)?

Today’s highest price of Agenus (AGEN) is $2.57.

Today’s lowest price of Agenus (AGEN) is $2.37.

What is today's market capitalisation of Agenus?

Today's market capitalisation of Agenus AGEN is 60.9M

What is the 52 Week High and Low Range of Agenus Stock (AGEN)?

  • 52 Week High

    $19.69

  • 52 Week Low

    $2.37

What are the historical returns of Agenus (AGEN)?

  • 1 Month Returns

    -31.14%

  • 3 Months Returns

    -51.8%

  • 1 Year Returns

    -82.79%

  • 5 Years Returns

    -94.87%

Who is the Chief Executive Officer (CEO) of Agenus ?

Dr. Garo H. Armen Ph.D. is the current Chief Executive Officer (CEO) of Agenus.